<PAGE>

[BIOCIRCUITS LETTERHEAD]


                                            Contact:  John Kaiser
                                                      President & CEO
                                                      Biocircuits Corp.
                                                      (408) 752-8706

FOR IMMEDIATE RELEASE

                       BIOCIRCUITS ANNOUNCES FINANCING 
                         AND FIRST QUARTER RESULTS

SUNNYVALE, CA--APRIL 16, 1997--Biocircuits Corporation (Nasdaq: BIOC) 
announced today the closing of a private placement in the aggregate amount of 
approximately $8.0 million, which resulted in gross proceeds to the Company 
of approximately $1.7 million on April 15, additional gross proceeds of 
approximately $5.5 million to be received upon completion of certain 
milestones at the end of the second quarter and additional gross proceeds of 
approximately $0.8 million to be received upon the completion of certain 
other milestones at year end 1997. 

The Company also announced today its estimated financial results for the 
first quarter ended March 31, 1997. The Company reported a net loss of 
approximately $3.5 million or $0.41 per share, compared to a net loss of $3.6 
million or $0.49 per share in the fourth quarter of 1996. 

"In the first quarter, Biocircuits reported revenue from product sales to 
distributors of $234,000. The importance of launching the TSH test in late 
December of 1996 was apparent in the first quarter as installations of 
IOS-TM-systems in customer sites doubled from year end 1996 with a 
significant number sold but not yet installed at the end of the quarter. We 
were encouraged enough from these results that during March we added four 
people to the sales force, bringing the total to nine. Adding people to the 
sales force to train and assist distributor sales people is a key element to 
increasing results," said John Kaiser, President and Chief Executive Officer.

Mr. Kaiser also announced that effective April 3rd the Biocircuits work force 
was reduced from 92 to 54 employees. "The reductions occurred throughout the 
Company with the exception of the sales force which was increased in March. 
These planned changes have resulted in a significant expense reduction but 
should not materially effect sales in the near term although some longer term 
projects affecting product development and cartridge cost reduction will be 
necessarily delayed," said Mr. Kaiser.

In addition to the currently marketed T4 and T-Uptake and TSH cartridges, 
Biocircuits has received FDA clearance to market Serum hCG and Quantitative 
hCG cartridges for diagnosing pregnancy and for following difficult 
pregnancies. Biocircuits will continue development of three additional assays 
for its IOS system: a PSA test for the management of prostate cancer, a 
Digoxin test for monitoring the therapeutic usage of this drug in the 
treatment of heart disease and a Free T4 test for diagnosing true clinical 
thyroid status. 

                                    - more -


<PAGE>

BIOCIRCUITS CORPORATION
Biocircuits Announces Financing and First Quarter Results
Page 2



With its IOS system, Biocircuits is targeting the approximately 41,000 small 
to medium-sized physician office practices and free-standing alternate site 
laboratories which are licensed under CLIA for high or moderate complexity 
testing. 

Actual results may differ materially from the above forward-looking 
statements due to a number of important factors, and will be dependent upon 
the Company's ability, directly or through third parties, to successfully 
manufacture and market its existing and proposed products, as well as the 
timely development and regulatory approval of additional products. These 
factors are more fully discussed in the Company's most recent report on Form 
10-K. 

                                   ###